Article Text

Download PDFPDF
  1. Alistair Lindsay, Editor

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

General cardiology

Intramyocardial bone marrow cell injection improves myocardial perfusion

Animal studies have suggested that bone marrow cell injection can improve myocardial perfusion and ventricular function in chronic ischaemia, but the two randomised trials performed to date in humans have yielded conflicting results.

To investigate the effect of intramyocardial bone marrow cell injection on myocardial perfusion and left ventricular (LV) function further, Van Ramshorst et al randomised 50 patients with chronic myocardial ischaemia to either intramyocardial injection of autologous bone marrow cells or placebo solution (25 patients per group). The primary outcome measure was myocardial perfusion as assessed by the summed stress score, a 17-segment score for stress myocardial perfusion assessed by 99mTc tetrofosmin single-photon emission computed tomography (SPECT), while secondary measures included LV ejection fraction (LVEF) as assessed by MRI, Canadian Cardiovascular Society (CCS) angina class and the Seattle Angina Questionnaire quality-of-life score.

After 3-months of follow-up, the summed stress score improved from a mean (SD) of 23.5 (4.7) to 20.1 (4.6) (p<0.001) in the bone marrow cell group, compared with a decrease from 24.8 (5.5) to 23.7 (5.4) (p = 0.004) in the placebo group. In those patients who underwent MRI, a 3% increase in LVEF was seen in the bone marrow cell-treated patients at 3 months (95% CI 0.5% to 4.7%), but the placebo group showed no improvement. Improvements in CCS class quality-of-life scores were significantly greater in bone marrow cell-treated patients than in placebo-treated patients (p = 0.03 and p = 0.04, respectively).


In this small study of patients with angina refractory to medical treatment, intramyocardial bone marrow injection resulted in a statistically significant improvement in myocardial perfusion, ejection fraction and quality-of-life at 3 months. Whether this translates into an improvement in morbidity and mortality outcomes requires verification in further long-term studies.

▸ Van Ramshorst J, Bax JJ, Beeres SLMA, et al. Intramyocardial bone marrow cell injection for chronic myocardial …

View Full Text


  • Provenance and peer review Not commissioned; not externally peer reviewed.